Rationale: Whether pharmacological therapy alters decline in FEV1 in chronic obstructive
pulmonary disease remains controversial. Because pharmacotherapy improves health …

Only long-term home oxygen therapy has been shown in randomised controlled trials to
increase survival in chronic obstructive pulmonary disease (COPD). There have been no …

Background Clinicians are faced with an increasingly difficult choice regarding the optimal
bronchodilator for patients with chronic obstructive pulmonary disease (COPD) given the …

Background Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic
obstructive pulmonary disease (COPD), but their effect on survival is unknown. Methods We …

Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Background Interactions between spirometry and patient-reported outcomes in COPD are
not well understood. This systematic review and study-level analysis investigated the …

Lung function in chronic obstructive pulmonary disease (COPD) can be improved acutely by
oral corticosteroids and bronchodilators. Whether clinical improvement can be maintained …

Rationale: Exacerbations are key drivers of morbidity and mortality in chronic obstructive
pulmonary disease (COPD). Objectives: We compared the relative efficacy of the long-acting …

We review the cardiac safety of the drugs available at present for the maintenance treatment
of chronic obstructive pulmonary disease (COPD) in stable disease, focusing on inhaled …

Background: β 2-Agonists andcorticosteroids or theophylline can interact to produce
beneficialeffects on airway function in asthma, but this has not been establishedin COPD …